The Association of the British Pharmaceutical Industry (ABPI) has today published details of payment to the Department of Health (DH) under the five-year Pharmaceutical Price Regulation Scheme (PPRS).
15 Jun 2016 Posted in By Press Office
The figures show that the companies who are voluntarily signed up to the scheme have paid £367million between September 2015 and March 2016, taking total payments to £1.296Billion. However, the overall spend on medicines covered by the scheme has remained flat over the past 12 months.
|PPRS Year 2014/15 – comprising Q4 2014 + Q1 2015||£4,117M|
|PPRS Year 2015/16 – comprising Q4 2015 + Q1 2016||£4,116M|
ABPI's Director of Pricing and PPRS, David Watson, said: "Today's figures show that the medicines spend under the PPRS is lower than anticipated when the scheme began, however the scheme remains important overall in helping the Department of Health and the NHS budget for medicines. We are reviewing the figures on an ongoing basis with the Department of Health."
The PPRS is a voluntary deal between the industry and the Department of Health which helps the NHS budget for new medicines. If the NHS spends over an agreed limit, the industry pays back the difference. Since the scheme started in 2014, the total figure paid back by companies has reached £1.296Billion. The deal was agreed primarily to help stimulate growth in the use of new medicines for NHS patients, help the NHS budget effectively and give patients better access to innovative treatments.
ABPI Press Office
Telephone during work hours (9am to 5pm Monday to Friday):
+44 (0) 20 7747 7147 or +44 (0) 20 7747 1441
Telephone out of hours (5pm to 9am and weekends):
+44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies supplying around 90 per cent of all medicines used by the NHS, and are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.